Request Demo
Last update 19 Dec 2025
BRL-303
Last update 19 Dec 2025
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms Anti CD19 universal chimeric antigen receptor T cell therapy(Bioray), BRL 303, BRL303 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with BRL-303NCT06485232
An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System
NCT06681337
A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
ChiCTR2000040018
Phase the Safety and Tolerability of CD19 Universal Chimeric Antigen Receptor T Cells in Subjects with R/R CD19 positive B cell malignant tumors
100 Clinical Results associated with BRL-303
Login to view more data
100 Translational Medicine associated with BRL-303
Login to view more data
100 Patents (Medical) associated with BRL-303
Login to view more data
100 Deals associated with BRL-303
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis | Phase 1 | China | 28 Feb 2025 | |
| Myasthenia Gravis | Phase 1 | China | 28 Feb 2025 | |
| Neuromyelitis Optica | Phase 1 | China | 28 Feb 2025 | |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 1 | China | 28 Feb 2025 | |
| Lupus Nephritis | Phase 1 | - | 25 Nov 2024 | |
| Systemic Lupus Erythematosus | IND Approval | China | 12 Dec 2025 | |
| Stomach Cancer | Preclinical | China | 14 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free